The Wistar Institute Of Anatomy And Biology

The Wistar Institute Of Anatomy And Biology, an independent tax-exempt biomedical research institute headquartered in Philadelphia, Pennsylvania, receives federal research funding primarily as a prime grant recipient under the National Institutes of Health grant programs, with secondary funding from the Defense Health Agency and other federal agencies. The Institute operates across basic and translational research in cancer biology, immunology, vaccine development, and HIV/AIDS research, competing in full-and-open grant programs rather than set-aside contract categories.

The Institute's federal funding footprint is dominated by research grants rather than service contracts. Across 351 awards (282 as prime, 69 as subrecipient), the portfolio concentrated in two customer agencies accounts for 74% of recent award volume: the National Cancer Institute and the broader National Institute of Allergy and Infectious Diseases (NIAID) lead by count, while the Defense Advanced Research Projects Agency and NIAID anchor the portfolio by potential value, with combined figures of $26.9 million and $25 million respectively. Award activity accelerated from 2023 through 2026—from eight awards in 2023 to 34 in 2026—and approximately 36 awards reach completion within the next twenty-four months, creating recompete opportunity across the Institute's research portfolio.

Representative prime grant work spans cancer immunology, HIV cure research, and vaccine development. The National Cancer Institute funded $780.764 thousand (awarded April 15, 2026) to investigate branched-chain amino acid oxidation in tumor-associated macrophages to enhance anti-tumor immunity in pancreatic ductal adenocarcinoma; $651.940 thousand (May 19, 2026) to elucidate targetable mechanisms of immunosuppressive neutrophils in glioblastoma; and $473.624 thousand (April 3, 2026) to investigate myeloid cell-derived interleukin 1B in metastatic ovarian cancer chemoresistance. The National Institute of Allergy and Infectious Diseases awarded $889.101 thousand (August 21, 2026) to develop enhanced natural killer cell-based strategies targeting HIV reservoirs and $707.928 thousand (July 13, 2026) for epitope-engineered hematopoietic stem cell research to enable CAR-T cell-mediated CD4 depletion as an HIV cure strategy. The Defense Health Agency funded $1.050 million (November 1, 2026) to investigate metabolic control of immune cold CCNE1-driven ovarian cancers and $1.194 million (September 1, 2023) for developing rational approaches for acral melanoma treatment. The National Institute of General Medical Sciences supported $591.549 thousand (June 1, 2026) on RNA polymerase II transcriptional integrity through the Integrator complex and PP2A phosphatase and $506.550 thousand (April 1, 2026) on TIM4+ macrophage development mechanisms.

The Wistar Institute operates as a prime recipient on the overwhelming majority of its federal work (80% of awards), indicating a research-focused enterprise that builds its own investigator teams rather than depending on larger prime contractors for deployment. Across SCI-reportable federal service contracts, the Institute appeared as a named subcontractor in four records spanning FY2022–FY2025, delivering roughly 1.0 to 1.5 FTEs annually on federal service work. This minimal SCI footprint reflects the Institute's positioning as a grant-funded research organization rather than a service contractor; SCI captures contracts above $150,000, while the Institute's federal revenue flows predominantly through NIH research grants outside SCI scope. Named subcontract relationships include work as a sub-recipient under Icahn School of Medicine at Mount Sinai (August 18, 2022) on the Collaborative Influenza Vaccine Innovation Centers program to perform polyclonal epitope mapping and glycan research on influenza vaccine responses, and sub-award arrangements with academic partners including the University of Pennsylvania, Thomas Jefferson University, Emory University, and Johns Hopkins University spanning HIV vaccine development, cancer immunotherapy, genome regulation, and biomarker discovery.

The Institute's grant sub-award footprint demonstrates deep collaborative research networks across academic medical centers and research universities, with approximately 69 sub-award relationships. Representative sub-recipients and collaborative work include the University of Pennsylvania (multiple agreements on humanized mouse models for melanoma and T cell engineering, B cell vaccine responses, and bispecific antibody development); Thomas Jefferson University (on P53 genetics, Mdm2-targeted PROTACs, and analyses supporting pancreatic cancer research); Emory University (on HIV immune homeostasis and vaccine development); the Johns Hopkins University (on EBV methylome characterization and microglial function in HIV-induced sleep deficits); Duke University (on melanoma brain metastasis models); Yale University (on leukapheresis and rectal biopsy sample collection from ART-suppressed HIV patients); and Virginia Commonwealth University (on lentivirus-like particle delivery of Cas12 ribonucleoprotein for HIV cure). Collaborative arrangements with University of Texas Health Science Center Houston, Northwestern University, and New York University extend work in glycomic modulation of HIV immunity and melanoma immunology.

The Institute positions itself as an independent research performer competing for federal peer-reviewed research funding in cancer immunology, infectious disease, and vaccine development. Its award trajectory and composition—dominated by NIH R01, R21, and project grants alongside Defense Health Agency Medical Research and Development awards—reflect a research institute model rather than a federal services contractor or systems integrator. Recompete activity over the next twenty-four months (36 awards completing) will anchor the Institute's pipeline across cancer research, HIV cure strategies, and immunotherapy development.